

ACS Cancer Conference 2025

March 12-14 | Phoenix, AZ

Increasing Access to and Diversity in Clinical Trials

Allison Martin, MD, MPH

Assistant Professor of Surgery and Population Health Sciences

Duke University School of Medicine

ACS Cancer Programs
American College of Surgeons

Disclosures

- Karios Technologies (shareholder)
- Contraline, Inc. (shareholder)

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Outline

- Conceptual Framework
- Barriers to Enrollment
 - Implicit Bias
 - Access
 - Study Design
- Barriers to Recruitment
- Opportunities for Intervention
- Industry and New Technology

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Clinical Trial Access/Enrollment

- >75% of US cancer clinical trials do not representatively recruit their target population
- **Lack of representation = Lack of generalizability**

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Participate in Cancer Research

About Cancer Clinical Research

Research Needs People from All Backgrounds

Personal Stories

How to Participate >

Plan Your Participation >

Clinical Trials Information >

Find a Clinical Trial >

Cancer Research Needs People from All Backgrounds

The goal of cancer research is to advance treatments and care for everyone. While the number of people from different backgrounds who take part in cancer research has increased over time, we need your help to make more progress.

ON THIS PAGE


- [Examples of diversity needed in cancer research](#)
- [How diversity improves cancer research](#)
- [Everyone can take part](#)
- [Ways to participate in cancer research](#)

Examples of diversity needed in cancer




The goal of cancer research is to advance treatments and health care for everyone.

Conceptual Framework: Clinical Trial Disparities



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Conceptual Framework: Clinical Trial Disparities



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Conceptual Framework: Pancreas Cancer Trials

BARRIERS TO PANCREATIC CANCER CLINICAL TRIAL ENROLLMENT



Patient-Level

Lack of trial access in disadvantaged/lower income communities

Inadequate education regarding importance and impact of participating in pancreatic cancer clinical trials



Clinician-Level

Lack of clinician access of pancreatic cancer clinical trials

Bias in clinician-provider communications secondary to racial discordance



System-Level

No consideration for equitable enrollment in clinical trials

Inadequate use of community leaders or social media to reach trial participants



Pancreatic Cancer Trials

Examine appropriateness of eligibility criteria to achieve study primary outcome

Consider cost and socioeconomic factors related to trial participation

Barriers to Clinical Trial Enrollment

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Implicit Bias

Both conscious and unconscious bias that may influence care delivered

- Individual-Level (“provider attitudes and beliefs”)
 - Previously established care relationships
 - Supportive communication
 - Length of clinician-patient interaction
- System-Level (“institutional culture”)
 - Likelihood of participation and/or anticipated non-compliance with study protocols
 - “Less ideal study candidates.”
 - Communication with minority participants perceived to be difficult

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Example: Qualitative Approach

- Interactions With Potential Minority Participants Were Perceived to Be Challenging
 - “African Americans I think have less knowledge. We take a little bit more time to explain to [them]...they have a lot of questions.” (Study PI)
- Potential Minority Participants Are Not Perceived to Be Ideal Study Candidates
 - “I think physicians think about whether or not the patient would comply with the study. Patient compliance I think is one of the things they think about... Well, he lives by himself. How are we going to make sure he does all this?” (Research Staff)

Access to Trials and Study Design Barriers

- Geographic proximity to trial sites
 - Area level measures of social vulnerability
 - Poverty rates
- Study design barriers
 - Disease-specific (e.g.
 - Patient-specific (e.g.
 - Comorbidity criteria
 - Study complexity (e.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group


Raymond U. Osarogiagbon¹, Diana Merino Vega², Lola Fashoyin-Aje³, Suparna Wedam³, Gwynn Ison³, Sol Atienza⁴, Peter De Porre⁵, Tithi Biswas⁶, Jamie N Holloway⁷, David S Hong⁸, Madison M Wempe², Richard L. Schilsky⁹, Edward S. Kim¹⁰, James L Wade III¹¹

Adams-Campbell LL, et al.. Journal of Clinical Oncology. 2004;22(4):730-4.

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Example: Clinical Trials Eligibility Criteria

- PDAC clinical trial traditional eligibility criteria:
 - Creatinine $\leq$ 1.5 mg/dL or CrCl <30 mL/min
 - History of other malignancy within prior 3 years
 - Known HIV infection
 - Known HBC or HCV
 - Uncontrolled diabetes mellitus
 - Coronary stenting within prior 6 months
- Black patients were more likely to be ineligible for participation compared with White patients (42.4% v. 33.2%)



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Riner, et al., J Clin Oncol. 2022 Mar 22;JCO2102492

Barriers to Clinical Trial Recruitment

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Patient-Level and Clinician-Level Factors

- Patient-physician communication differences
 - Differences in communication and information needs
 - Patient-level cultural perspectives

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Patient-Level Cultural Perspectives

How Do Black People with Cancer View Clinical Research?

[Subscribe](#)

November 15, 2024, by Nadia Jaber

Findings from a small study suggest that more Black than White, Asian, or patients of other races distrust medical research and have spiritual beliefs about medical research. The study asked about 100 people being treated for cancer whether they agreed with certain statements about research.

The findings may help research staff talk with and recruit more Black patients for clinical trials, said the study's leader, Charlyn Gomez, a medical student at the University of Maryland School of Medicine.

Black people make up about 14% of the U.S. population but only 10% of clinical trial participants. Clinical trial participation is important because it provides people with the opportunity to access emerging cancer treatments, tests, and approaches to improving cancer care.

More Black than non-Black participants of the new study agreed with statements like, "medical research is designed to harm minorities," and "God determines wellness, not research," Ms. Gomez reported October 1 at the American Society for Radiation Oncology (ASTRO) annual meeting in Washington, D.C.



More Black than non-Black participants of the new study agreed [with](#) statements like, "medical research is designed to harm minorities," and "God determines wellness, not research," Ms. Gomez reported October 1 at the American Society for Radiation Oncology (ASTRO) annual meeting in Washington, D.C.

Credit: iStock/FatCamera

National Cancer Institute, National Institutes of Health (2025)

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Patient-Level and Clinician-Level Factors

- Patient-physician communication differences
 - Differences in communication and information needs
 - Patient-level cultural perspectives
- Trial awareness (geography)
 - Clinician-Level
 - Inadequate information about trials (community MDs, 75% vs. oncologists 36%).
 - Patient-Level
 - Rural residents less likely to report discussion of clinical trials with their oncologists (compared to inner-city)
- Patient-level resources

Interventions targeted at enrollment

Patients

- Culturally appropriate marketing materials for patients
 - Endorsements by trusted community leaders and survivors
 - Vary the marketing approach
- Targeted educational interventions
- Clinical navigation programs

Clinicians

- Targeted outreach to community physicians
 - Long-term community outreach partnerships

Pinto HA, et al. Ann Epidemiol. 2000;10(8 Suppl):S78-84.

Du W, Mood D, Gadgeel S, Simon MS.. Journal of Thoracic Oncology. 2008;3(1):23-9


© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Opportunities for Intervention

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Example: Social Media Advertising

- Salud America!
 - Effort to improve clinical trial participation
 - Social media advertising
 - Facebook, Twitter, and Instagram
 - Directs to website with patient stories
- Get Randomized
 - Public awareness initiative
 - 9.2% increase in awareness/understanding of RCT
 - ~1% increase in enrollment



Ramirez AG, et al. Health Education & Behavior. 2011;38(3):251-60.
<https://salud-america.org/trials/>

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Most Common Types of Interventions Implemented

Older adults: 4
Racial/Ethnic minorities: 15
Sexual/Gender minorities: 1
Financial barriers: 2
Health literacy: 1
Access to clinical trial screening
to community hospitals: 1

Recruitment in the community/in partnership
with trusted community groups or online vs
standard hospital recruitment

Educational modalities (community session,
pamphlets, videos)

Assignment of trained patient navigators /
patient screening employees

Provider/ staff-centered training



Takeaways From Successful Interventions




© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

"no photos" icon by Muhammad Shabraiz from Noun Project.

Industry and New Technology

© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Industry/Pharma



Solutions

Catalog ▾

Organizations ▾

Individuals ▾

Webinar Demo:

Webinar Demo

Research Equity and the Part We Play

Presented by:
Nicole Fisher, BS
AbbVie
Clinical misTrials Podcast

©2022 Biomedical Research Alliance of New York LLC
CITI Program is a division of BRANY



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

<https://www.merckclinicaltrials.com/diversity-inclusion/>

AI/Site Selection Tools

Artificial Intelligence


- Identify trial eligible patients
- Synthesize large sets of data
- “Bias-free” recommendations

Site Selection Tools

- Example: TriNetX
 - Cloud-based platform to query and analyze longitudinal, de-identified data



TriNetX



© American College of Surgeons. Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Chow R, et al. J Natl Cancer Inst. 2023 Apr 11;115(4):365-374.

ACS Cancer Conference 2025

March 12-14 | Phoenix, AZ

Increasing Access to and Diversity in Clinical Trials

Allison Martin, MD, MPH

allison.martin@duke.edu

@globalsurgallie

